跳到主要內容

臺灣博碩士論文加值系統

(44.201.97.224) 您好!臺灣時間:2024/04/18 02:56
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:高敬彥
研究生(外文):GAO, JING-YAN
論文名稱:I. 合成色胺酮衍生物做為抗肝癌之藥物 II. 合成1,2,3-三取代苯并咪唑做為新型抗腫瘤藥物 III. 設計合成全反式維甲酸類緣物做為抗癌藥物
論文名稱(外文):I. Synthesis of tryptanthrin derivatives as anti-hepatocellular carcinoma agents. II. Synthesis of novel 1,2,3-trisubstituted benzimidazoles as antitumor agents. III. Design and synthesis of novel ATRA derivatives as anticancer agents.
指導教授:連金城連金城引用關係
指導教授(外文):Lien, Jin-Cherng
口試委員:莊聲宏林煇章王昭能洪欣儀
口試委員(外文):Juang, Shin-HunLin, Hui-ChangWang, Chao-NengHung, Hsin-Yi
口試日期:2022-08-22
學位類別:博士
校院名稱:中國醫藥大學
系所名稱:藥學系博士班
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2022
畢業學年度:110
語文別:中文
論文頁數:194
中文關鍵詞:色胺酮肝細胞癌氧化壓力全反式維生素甲酸白血病脯氨醯肽醯順反異構酶苯并咪唑非小細胞肺癌結腸癌細胞存活率試驗
外文關鍵詞:tryptanthrinHCCROSATRAPin1benzimidazoleantitumorNSCLC
相關次數:
  • 被引用被引用:0
  • 點閱點閱:104
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
目次
中文摘要 II
Abstract IV
目次 VI
圖目次 IX
表目次 XIV
縮寫對照表 XV
緒論 1
I. 合成色胺酮衍生物做為抗肝癌之藥物 2
第一章 前言 2
1.1手術治療 3
1.2藥物治療 3
第二章 研究之動機與目的 6
第三章 討論 8
3.1化學合成方法 8
3.2藥物對 Hep3B cells的MTT assay 10
3.3化合物A1與化合物A6誘導細胞週期阻滯 12
3.4 化合物A1與化合物A6在 Hep3B 細胞中誘導Caspase 8依賴性細胞凋亡 14
3.5化合物A1與化合物A6調節Akt和MAPK的信號傳導 16
3.6化合物A1與化合物A6增加產生ROS 18
3.7藥物構效關係探討 22
3.8化合物之製備 23
第四章 結論 27
第五章 實驗部分 29
5.1試藥來源 29
5.2重要儀器與實驗材料 30
II. 合成1,2,3-三取代苯并咪唑做為新型抗腫瘤藥物 32
第六章 前言 32
6.1癌症現況 32
6.2EGFR 33
6.3 VEGFR 35
6.4 IGF 36
6.5 p53 37
6.6 KRAS做為抗癌藥的標靶 39
6.7 Cancer cell line選用 48
第七章 研究之動機與目的 50
7.1苯并咪唑衍生物目前的研究概況 50
7.2苯并咪唑衍生物合成方法 54
7.3 先期探索之研究成果 56
第八章討論 61
8.1 化學合成方法 61
8.2 結構解析 67
8.3 縮寫與代號對照表 77
8.4 藥物抑制cancer cell line活性測試 80
8.5 Kst系列藥物對於Western blot分析 89
8.6 分子模擬討論Kst4Me與KRAS G12-V突變蛋白之結合關係 93
8.7 分子模擬討論Kst4Mo與KRAS G12-S突變蛋白之結合關係 95
8.8 分子模擬對於Kst系列藥物之ADME與毒性模擬分析 99
8.9 SAR研究 101
8.10 化合物之製備 106
第九章 結論 117
第十章 實驗部分 118
10.1試藥來源 118
10.2重要儀器與實驗材料 119
III. 設計合成全反式維甲酸類緣物做為抗癌藥物 121
圖譜資料 122
參考文獻 184



1.Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30.
2.Maluccio, M.; Covey, A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA A Cancer J. Clin. 2012, 62, 394–399
3.Malik, A.; Thanekar, U.; Amarachintha, S.; Mourya, R.; Nalluri, S.; Bondoc, A.; Shivakumar, P. “Complimenting the Complement”: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front. Oncol. 2020, 10, 627701.
4.Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30.
5.Maluccio, M.; Covey, A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA A Cancer J. Clin. 2012, 62, 394–399
6.Malik, A.; Thanekar, U.; Amarachintha, S.; Mourya, R.; Nalluri, S.; Bondoc, A.; Shivakumar, P. “Complimenting the Complement”: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front. Oncol. 2020, 10, 627701.
7.Sarker, S.D.; Nahar, L.; Miron, A.; Guo, M. Charpter Two—Anticancer Natural Products; Elservier Inc.: Amsterdam, The Netherlands, 2020; Volume 55, pp. 45–75.
8.Li, F.; Jiang, T.; Li, Q.; Ling, X. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am. J. Cancer Res. 2017, 7, 2350–2394.
9.Sibaud, V.; Lebœuf, N.R.; Roche, H.; Belum, V.R.; Gladieff, L.; Deslandres, M.; Montastruc, M.; Eche, A.; Vigarios, E.; Dalenc, F.; et al. Dermatological adverse events with taxane chemotherapy. Eur. J. Dermatol. 2016, 26, 427–443.
10.Sibaud, V.; Lebœuf, N.R.; Roche, H.; Belum, V.R.; Gladieff, L.; Deslandres, M.; Montastruc, M.; Eche, A.; Vigarios, E.; Dalenc, F.; et al. Dermatological adverse events with taxane chemotherapy. Eur. J. Dermatol. 2016, 26, 427–443.
11.Zou, P.; Koh, H.L. Determination of indican, isatin, indirubin and indigotin in Isatis indigotica by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21, 1239–1246.
12.Sarker, S.D.; Nahar, L.; Miron, A.; Guo, M. Charpter Two—Anticancer Natural Products; Elservier Inc.: Amsterdam, The Netherlands, 2020; Volume 55, pp. 45–75.
13.Li, F.; Jiang, T.; Li, Q.; Ling, X. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am. J. Cancer Res. 2017, 7, 2350–2394.
14.Sibaud, V.; Lebœuf, N.R.; Roche, H.; Belum, V.R.; Gladieff, L.; Deslandres, M.; Montastruc, M.; Eche, A.; Vigarios, E.; Dalenc, F.; et al. Dermatological adverse events with taxane chemotherapy. Eur. J. Dermatol. 2016, 26, 427–443.
15.Sibaud, V.; Lebœuf, N.R.; Roche, H.; Belum, V.R.; Gladieff, L.; Deslandres, M.; Montastruc, M.; Eche, A.; Vigarios, E.; Dalenc, F.; et al. Dermatological adverse events with taxane chemotherapy. Eur. J. Dermatol. 2016, 26, 427–443.
16.Zou, P.; Koh, H.L. Determination of indican, isatin, indirubin and indigotin in Isatis indigotica by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21, 1239–1246.
17.Muluye, R.A.; Bian, Y.; Alemu, P.N. Anti-inflammatory and Antimicrobial Effects of Heat-clearing Chinese Herbs: A Current Review. J. Tradit. Complement. Med. 2014, 4, 93–98.
18.Li, Z.-T.; Li, L.; Chen, T.-T.; Li, C.-Y.; Wang, D.-Q.; Yang, Z.-F.; Zhong, N.-S. Efficacy and safety of Ban-Lan-Gen granules in the treatment of seasonal influenza: Study protocol for a randomized controlled trial. Trials 2015, 16, 126.
19.Tsai, T.-Y.; Livneh, H.; Hung, T.-H.; Lin, I.-H.; Lu, M.-C.; Yeh, C.-C. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide population-based cohort study. BMJ Open 2017, 7, e014571.
20.Chan, H.-L.; Yip, H.-Y.; Mak, N.-K.; Leung, K.-N. Modulatory Effects and Action Mechanisms of Tryptanthrin on Murine Myeloid Leukemia Cells. Cell. Mol. Immunol. 2009, 6, 335–342.
21.Kim, W.; Youn, H.; Kwon, T.; Kang, J.; Kim, E.; Son, B.; Yang, H.J.; Jung, Y.; Youn, B. PIM1 kinase inhibitors induce radio-sensitization in non-small cell lung cancer cells. Pharmacol. Res. 2013, 70, 90–101.
22.Liao, X.; Zhou, X.; Mak, N.K.; Leung, K.N. Tryptanthrin inhibits angiogenesis by targeting the VEGFR2-mediated ERK1/2 signalling pathway. PLoS ONE 2013, 8, e82294.
23.Shankar, G.M.; Alex, V.V.; Nisthul, A.A.; Bava, S.V.; Sundaram, S.; Retnakumari, A.P.; Chittalakkottu, S.; Anto, R.J. Pre-clinical evidence for the efficacy of tryptanthrin as a potent suppressor of skin cancer. Cell Prolif. 2019, 53, e12710.
24.Yu, S.-T.; Chen, T.-M.; Tseng, S.-Y.; Chen, Y.-H. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem. Biophys. Res. Commun. 2007, 358, 79–84.
25.Ramandeep Kaur, Sundeep Kaur Manjal, Ravindra K. Rawal, Kapil Kumar, Recent synthetic and medicinal perspectives of tryptanthrin, Bioorganic & Medicinal Chemistry, Volume 25, Issue 17, 2017, Pages 4533-4552, ISSN 0968-0896,
26.Dimri, M.; Satyanarayana, A. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers 2020, 12, 491.
27.Mroweh, M.; Roth, G.; Decaens, T.; Marche, P.N.; Lerat, H.; Macek Jílková, Z. Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int. J. Mol. Sci. 2021, 22, 1794.
28.Cui, J.; Shen, H.-M.; Lim, L.H.K. The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets. Pharmaceuticals 2020, 13, 432.
29.Devasagayam, TPA; Tilak JC, Boloor KK, Sane Ketaki S, Ghaskadbi Saroj S, Lele RD. Free Radicals and Antioxidants in Human Health: Current Status and Future Prospects. Journal of Association of Physicians of India (JAPI). October 2004, 52: 796.
30.Yu, S.-T.; Chern, J.-W.; Chen, T.-M.; Chiu, Y.-F.; Chen, H.-T.; Chen, Y.-H. Cytotoxicity and reversal of multidrug resistance by tryptanthrin-derived indoloquinazolines. Acta Pharmacol. Sin. 2010, 31, 259–264.
31.Miceli, N.; Filocamo, A.; Ragusa, S.; Cacciola, F.; Dugo, P.; Mondello, L.; Celano, M.; Maggisano, V.; Taviano, M.F. Chemical Characterization and Biological Activities of Phenolic-Rich Fraction from Cauline Leaves of Isatis tinctoria L. (Brassicaceae) Growing in Sicily, Italy. Chem. Biodivers. 2017, 14, e1700073.
32.https://www.mohw.gov.tw/cp-16-70314-1.ht ml
33.Vasudev, N. S.; Reynolds, A. R., Anti-angiogenic therapy for cancer: current progress, unresolvedquestions and future directions. Angiogenesis 2014, 17 (3), 471-94.
34.H. Guan, Y. Du, Y. Ning, X. Cao Future Med. Chem., 31 (2017), pp. 48-60
35.Phillip A. Schwartz, Brion W. Murray, Protein kinase biochemistry and drug discovery, Bioorganic Chemistry, Volume 39, Issues 5–6, 2011, Pages 192-210
36.E Martinelli, R De Palma, M Orditura, F De Vita, F Ciardiello, Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy, Clinical and Experimental Immunology, Volume 158, Issue 1, October 2009, Pages 1–9
37.Mahsa Toolabi, Setareh Moghimi, Tayebeh Oghabi Bakhshaiesh, Somayeh Salarinejad, Ayoub Aghcheli, Zaman Hasanvand, Elahe Nazeri, Ali Khalaj, Rezvan Esmaeili, Alireza Foroumadi, 6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: Design, synthesis and structure-activity relationship studies, European Journal of Medicinal Chemistry, Volume 185, 2020, 111786, ISSN 0223-5234
38.K. Ohashi, L.V. Sequist, M.E. Arcila, C.M. Lovly, X. Chen, C.M. Rudin, et al. Clin. Cancer Res., 19 (2013), pp. 2584-2591
39.Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res. 2017 Jun 1;77 (11):2990-3000. doi: 10.1158/0008-5472.CAN-16-2300. Epub 2017 Apr 17. PMID: 28416483; PMCID: PMC5467531.
40.Zhang Q, Zheng P, Zhu W. Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present). Molecules. 2020 Jun 8;25 (11):2666.
41.Wang J., Chen J., Guo Y., Wang B., Chu H. Strategies targeting angiogenesis in advanced non-small cell lung cancer. Oncotarget. 2017; 8: 53854-53872. Retrieved
42.Bhattacharya R, Ye XC, Wang R, Ling X, McManus M, Fan F, et al. Intracrine VEGF signaling mediates the activity of prosurvival pathways in human colorectal cancer cells. Cancer Res (2016) 76:3014–24.
43.A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling,BRITISH JOURNAL OF PHARMACOLOGY,2019 Oct,176 (20):4034-4049
44.Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928.
45.Gee JM, Robertson JF, Gutteridge E, et al.et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer. 2005;12:S99–S111. Suppl. 1
46.Camirand A, Zakikhani M, Young F, et al.et al. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res. 2005;7:R570–579.
47.Zimmermann K, Wittman MD, Saulnier MG, Velaparthi U, Sang X, Frennesson DB, Struzynski C, Seitz SP, He L, Carboni JM, Li A, Greer AF, Gottardis M, Attar RM, Yang Z, Balimane P, Discenza LN, Lee FY, Sinz M, Kim S, Vyas D. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20 (5):1744-8.
48.Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413–431 (2009).
49.Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
50.Tisato V, et al. J Hematol Oncol. 2017;10:133.
51.McBride, O. W. et al. Regional chromosomal localization of N-ras, K-ras-1, K-ras-2 and myb oncogenes in human cells. Nucleic Acids Res 11, 8221–8236 (1983).
52.Chang, E. H. et al. Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc. Natl Acad. Sci. USA 79, 4848–4852 (1982).
53.Seger, R.; Krebs, E.G. The MAPK signaling cascade. FASEB J. 1995, 9, 726–735.
54.Huang, L., Guo, Z., Wang, F. et al. KRAS mutation: from undruggable to druggable in cancer. Sig Transduct Target Ther 6, 386 (2021).
55.Prior, I. A., Hood, F. E. & Hartley, J. L. The Frequency of Ras Mutations in Cancer. Cancer Res 80, 2969–2974 (2020).
56.Martinelli, E., Morgillo, F., Troiani, T. & Ciardiello, F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treat. Rev. 53, 61–69 (2017).
57.Fruman, D. A. et al. The PI3K Pathway in Human Disease. Cell 170, 605–635 (2017).
58.Kilic, U. et al. Particular phosphorylation of PI3K/Akt on Thr308 via PDK-1 and PTEN mediates melatonin’s neuroprotective activity after focal cerebral ischemia in mice. Redox Biol. 12, 657–665 (2017).
59.She, Q.-B. et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8, 287–297 (2005).
60.Hunter, J. C. et al. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol. Cancer Res. 13, 1325–1335 (2015).
61.In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C PNAS. June 2, 2014
62.Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503 (7477):548-551.
63.Barbacid, M. ras genes. Annu Rev. Biochem 56, 779–827 (1987).
64.In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C PNAS. June 2, 2014
65.Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, Chen JH, Firdaus SJ, Babbar A, Ren P, Liu Y. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discov. 2016 Mar;6 (3):316-29.
66.Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018 Jan 25;172 (3):578-589.e17.
67.Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575 (7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30. PMID: 31666701.
68.Hong DS, Fakih MG, Strickler JH, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020;383 (13):1207-1217. doi:10.1056/NEJMoa1917239
69.Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chicarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Hinklin RJ, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA. Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. J Med Chem. 2020 Jul 9;63 (13):6679-6693. doi: 10.1021/acs.jmedchem.9b02052. Epub 2020 Apr 6. PMID: 32250617
70.Jiao Liu, Rui Kang, Daolin Tang. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Therapy (2021)
71.Lin, DL; Chang, C. p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. The Journal of biological chemistry. 1996-06-21, 271 (25): 14649–52 [2019-11-29].
72.Giard, DJ; Aaronson, SA; Todaro, GJ; Arnstein, P; Kersey, JH; Dosik, H; Parks, WP. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. Journal of the National Cancer Institute. 1973-11, 51 (5): 1417–23 [2019-12-03].
73.Elmaaty AA, Darwish KM, Chrouda A, Boseila AA, Tantawy MA, Elhady SS, Shaik AB, Mustafa M, Al-Karmalawy AA. In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity. ACS Omega. 2021 Dec 22;7 (1):875-899. doi: 10.1021/acsomega.1c05519. PMID: 35036753; PMCID: PMC8757357.
74.Beck DE, Agama K, Marchand C, Chergui A, Pommier Y, Cushman M. Synthesis, and biological evaluation of new carbohy- drate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents Indotecan (LMP400) and Indimitecan (LMP776). J Med Chem. 2014; 57:1495- 1512.
75.Hartmann M, Zimmer CH. Investigation of cross-link forma- tion in DNA by the alkylating cytostatica IMET 3106, 3393 and 3943. Biochim Biophys Acta. 1972; 287:386-389
76..Weide R (2008) Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma. Ther Clin Risk Manag 4:727–732.
77.A Review on the Modern Synthetic Approach of Benzimidazole Candidate Mohd. Faheem,Anjali Rathaur,Apoorva Pandey,Dr. Vinay Kumar Singh,Dr. Anjani K. Tiwari, Volume5, Issue13 April 7, 2020, Pages 3981-3994
78.Rosell, R., Aguilar, A., Pedraz, C. et al. KRAS inhibitors, approved. Nat Cancer 2, 1254–1256 (2021).
79.Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discov. 2020 Aug;10 (8):1129-1139. doi: 10.1158/2159-8290.CD-20-0187. Epub 2020 May 19. PMID: 32430388; PMCID: PMC7416460.

電子全文 電子全文(網際網路公開日期:20270822)
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊